Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial

被引：30

作者：

Yue, D. ^{[1
]}

Wang, W. ^{[2
]}

Liu, H. ^{[3
]}

Chen, Q. ^{[4
,5
]}

Chen, C.

Zhang, J. ^{[6
]}

Bai, F. ^{[7
]}

Wang, C. ^{[8
]}

机构：

[1] Tianjin Med Univ Canc Inst & Hosp, Lung Canc Dept, Tianjin, Peoples R China

[2] Hunan Canc Hosp, Hunan, Peoples R China

[3] Liaoning Canc Hosp & Inst, Dept Breast Surg, Shenyang, Peoples R China

[4] Zhejiang Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China

[5] Fujian Med Univ Union Hosp, Neurol, Fuzhou, Peoples R China

[6] BeiGene USA Inc, Director Biostat, San Mateo, CA USA

[7] BeiGene Shanghai Co Ltd, Clin Dev, Shanghai, Peoples R China

[8] Tianjin Med Univ Canc Inst & Hosp, Lung Canc, Tianjin, Peoples R China

来源：

关键词：

D O I：

10.1016/j.annonc.2023.10.054

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA58

引用

页码：S1299 / S1299

页数：1